Valuation: Ipsen

Market Cap 11.94B 13.37B 11.1B 10.09B 18.99B 1,267B 19.33B 133B 52.15B 661B 50.19B 49.13B 2,115B P/E 2026 *
12.1x
P/E 2027 * 12x
Enterprise Value 10.68B 11.97B 9.93B 9.03B 16.99B 1,133B 17.29B 119B 46.66B 591B 44.9B 43.95B 1,892B EV / Sales 2026 *
2.33x
EV / Sales 2027 * 2.08x
Free-Float
40.65%
Yield 2026 *
1.05%
Yield 2027 * 1.07%
1 day+1.99%
1 week+4.95%
Current month+4.50%
1 month-7.36%
3 months-7.53%
6 months-8.78%
Current year+24.79%
1 week 141.6
Extreme 141.6
148.5
1 month 138.3
Extreme 138.3
160.7
Current year 116
Extreme 116
174
1 year 112.7
Extreme 112.7
174
3 years 87.95
Extreme 87.95
174
5 years 77
Extreme 77
174
10 years 34.2
Extreme 34.2
174
Manager TitleAgeSince
Chief Executive Officer 59 01/07/2020
Chief Executive Officer 57 01/01/2020
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 30/08/2005
Chairman 68 22/11/2010
Director/Board Member 69 01/06/2012
Date Insider Type Main position Quantity % Market Cap. Importance
21/09/26 Buy

Director

500 0.0006%
08/09/26 Buy

Director

500 0.0006%
03/09/26 Sell

Director

-1,000 0.0012%
Change 5-day change 1-year change 3-year change Capi.($)
+1.99%+4.95%+30.15%+25.85% 13.28B
+3.88%+7.59%+52.24%+104.06% 1,077B
-0.04%-1.07%+32.72%+61.06% 612B
+0.58%+4.42%+25.75%+93.21% 501B
-0.42%+3.17%+74.65%+41.06% 364B
+2.37%+7.66%+33.65%+50.58% 353B
+2.64%+6.95%+21.01%+44.38% 278B
+3.24%+6.78%+0.43%+15.73% 251B
+2.64%+7.56%+47.39%+52.76% 230B
+2.85%+7.57%+33.76%+99.80% 190B
Average +1.94%+1.81%+35.17%+58.85% 386.98B
Weighted average by Cap. +2.02%+1.58%+39.26%+71.51%

Financials

2026 *2027 *
Net sales 4.59B 5.14B 4.26B 3.88B 7.29B 487B 7.43B 51.2B 20.03B 254B 19.28B 18.87B 812B 4.71B 5.28B 4.38B 3.98B 7.5B 500B 7.63B 52.62B 20.59B 261B 19.82B 19.4B 835B
Net income 1.01B 1.13B 937M 853M 1.6B 107B 1.63B 11.26B 4.4B 55.83B 4.24B 4.15B 179B 1.02B 1.15B 951M 865M 1.63B 109B 1.66B 11.43B 4.47B 56.67B 4.3B 4.21B 181B
Net Debt -1.26B -1.41B -1.17B -1.06B -2B -133B -2.04B -14.03B -5.49B -69.59B -5.28B -5.17B -223B -2.15B -2.41B -2B -1.82B -3.42B -228B -3.48B -23.97B -9.38B -119B -9.03B -8.84B -380B
Projected Income Statement - Annual - Ipsen
Logo Ipsen
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (69.2%); - neuroscience (20.3%); - rare diseases (10.5%). At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide. Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
Employees
5,535
Date Price Change Volume
15/10/26 €148.50 +1.99% 145,250
14/10/26 €145.60 +2.10% 163,923
13/10/26 €142.60 -1.04% 99,154
12/10/26 €144.10 +0.98% 76,047
09/10/26 €142.70 +0.85% 63,464
Trader
Investor
Global
Quality
ESG MSCI
AA
MarketScreener Ratings - Ipsen
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
14
Last Close Price
145.60EUR
Average target price
164.29EUR
Spread / Average Target
+12.83%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ipsen